|
[ X
|
]
|
ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [NO FEE REQUIRED] FOR THE FISCAL YEAR ENDED JUNE 30, 2023, OR
|
|
[
|
]
|
TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [NO FEE REQUIRED] for the transition period from _________ to__________.
|
A.
|
Full title of the plan and the address of the plan, if different from that of the issuer named below: Procter & Gamble 1-4-1 Plan, Procter & Gamble Technical Centres Limited, Cobalt
12, Silver Fox Way, Cobalt Business Park, Newcastle upon Tyne NE27 0QW.
|
B.
|
Name of issuer of the securities held pursuant to the plan and the address of its principal executive office: The Procter & Gamble Company, One Procter & Gamble Plaza, Cincinnati, Ohio
45202
|
Item 1.
|
Audited statements of financial condition as of the end of the latest two fiscal years of the plan (or such lesser period as the plan has been in existence). (See Page 2)
|
Item 2.
|
Audited statements of income and changes in plan equity for each of the latest three fiscal years of the plan (or such lesser period as the plan has been in existence). (See Page 3)
|
PROCTER & GAMBLE
1-4-1 PLAN
Statements of Net Assets Available for Plan
Benefits as of June 30, 2023 and 2022, Statements
of Changes in Net Assets Available for Plan
Benefits for the Years Ended June 30, 2023, 2022
and 2021, and Report of Independent Registered
Public Accounting Firm
|
TABLE OF CONTENTS | |||
Page | |||
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | 1 | ||
FINANCIAL STATEMENTS: | |||
Statements of Net Assets Available for Plan Benefits as of June 30, 2023 and 2022 | 2 | ||
Statements of Changes in Net Assets Available for Plan Benefits for the Years Ended June 30, 2023, 2022 and 2021
|
3 | ||
Notes to Financial Statements as of June 30, 2023 and 2022 and for the Years Ended June 30, 2023, 2022, and 2021 |
4 | ||
2023
£
|
2022
£
|
|
ASSETS:
|
||
Investment in The Procter & Gamble Company common stock, at fair value (568,652 shares at June 30, 2023 and 595,300 shares at June 30, 2022)
|
68,362,803
|
70,568,001
|
Cash at bank and in hand
|
837,810
|
806,584
|
Total assets
|
69,200,613
|
71,374,585
|
LIABILITIES:
|
||
Due to participating Procter and Gamble companies (Note 7)
|
-
|
(766)
|
Total liabilities
|
-
|
(766)
|
NET ASSETS AVAILABLE FOR PLAN BENEFITS
|
69,200,613
|
71,373,820
|
ADDITIONS / (LOSSES):
|
2023
£
|
2022
£
|
2021
£
|
Contributions:
|
|||
Employee contributions
|
2,902,229
|
2,707,627
|
3,095,513
|
Employer contributions (Note 7)
|
2,902,229
|
2,707,627
|
3,095,513
|
Total contributions
|
5,804,458
|
5,415,254
|
6,191,026
|
Investment income / (expense):
Realized gain on shares sold (Note 4)
|
3,363,639
|
3,687,126
|
2,709,377
|
Net (depreciation) / appreciation in fair value of The Procter & Gamble Company
common stock (Note 4)
|
(2,531,552)
|
9,057,842
|
(2,656,850)
|
Dividends from The Procter & Gamble Company
common stock (Note 7)
|
1,439,983
|
1,306,432
|
1,188,514
|
Interest income / (expense)
|
15,841
|
350
|
(1,324)
|
Total investment income
|
2,287,911
|
14,051,750
|
1,239,717
|
Income from participating Procter & Gamble companies
(Note 7)
|
8,870
|
16,458
|
20,255
|
Total additions
|
8,101,239
|
19,483,462
|
7,450,998
|
DEDUCTIONS:
|
|||
Distributions and withdrawals to participants
|
(10,054,995)
|
(9,759,687)
|
(8,151,789)
|
Amounts paid to participating companies (Note 7)
|
(210,581)
|
-
|
-
|
Administrative expenses
|
(8,870)
|
(16,458)
|
(20,255)
|
Total deductions
|
(10,274,446)
|
(9,776,145)
|
(8,172,044)
|
(DECREASE) / INCREASE IN NET ASSETS
|
(2,173,207)
|
9,707,317
|
(721,046)
|
NET ASSETS AVAILABLE FOR PLAN BENEFITS:
|
|||
Beginning of year
|
71,373,820
|
61,666,503
|
62,387,549
|
End of year
|
69,200,613
|
71,373,820
|
61,666,503
|
1. |
DESCRIPTION OF THE PLAN
|
2. |
SIGNIFICANT ACCOUNTING POLICIES
|
3. |
FAIR VALUE MEASUREMENTS
|
3. |
FAIR VALUE MEASUREMENTS (CONTINUED)
|
Level 1
|
Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the plan has the ability to
access.
|
|
Level 2
|
Inputs to the valuation methodology include
• quoted prices for similar assets or liabilities in active markets;
• quoted prices for identical or similar assets or liabilities in inactive markets;
• inputs other than quoted prices that are observable for the asset or liability;
• inputs that are derived principally from or corroborated by observable market data by correlation or other means.
If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of
the asset or liability.
|
|
Level 3
|
Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
|
4. |
INVESTMENTS
|
2023
£
|
2022
£
|
2021
£
|
|
The Procter & Gamble Company
|
|||
common stock:
|
|||
Net (depreciation) / appreciation
|
(2,531,552)
|
9,057,842
|
(2,656,850)
|
2023
£
|
2022
£
|
2021
£
|
|||
Proceeds on sale of shares
|
8,244,518
|
8,831,003
|
6,614,060
|
||
Cost
|
(4,880,879)
|
(5,143,877)
|
(3,904,683)
|
||
Realized gain on shares sold
|
3,363,639
|
3,687,126
|
2,709,377
|
5. |
FEDERAL INCOME TAX STATUS
|
6. |
PARTICIPATING PROCTER & GAMBLE COMPANIES
|
7. |
RELATED PARTY TRANSACTIONS
|
8. |
PLAN TERMINATION
|
9. |
SUBSEQUENT EVENTS
|